Cor Vasa 2019, 61(6):623-624 | DOI: 10.1016/j.crvasa.2018.09.008

Idarucizumab administration in a patient with incarcerated bowel hernia

Ersin Doğanözü^a, Ilker Sahin^a, Emir Karacaglar^b, Senem Has Hasirci^c, Mehmet Zeki Buldanlı^d

^a Department of Cardiology, Çankiri State Hospital, Kirkevler Mahallesi, Kastamonu Caddesi, 18100 Merkez/Çankiri Merkez/Çankiri, Turkey

^b Department of Cardiology, Başkent University Faculty of Medicine, Ankara Hospital, Fevzi Çakmak Cd. 10. Sk. No:45, Bahçelievler Ankara, Turkey

^c Department of Cardiology, Yenimahalle State Hospital, Yeni Batı Mah., 2026. Caddesi, 2367 Sokak No:4, 06370 Batıkent, Yenimahalle/Ankara, Turkey

^d Department of General Surgery, Çankırı State Hospital, Kırkevler Mahallesi, Kastamonu Caddesi, 18100 Merkez/Çankırı Merkez/Çankırı, Turkey

Atrial fibrillation is the most common rhythm disorder worldwide. Oral anticoagulants are used in the treat- ment of atrial fibrillation. Non-vitamin K oral anticoagulants have been used more often because of the fact that they are more effective and safer than conventional warfarin therapy. The absence of antidote in the majority of new generation oral anticoagulants leads to some difficulties in clinical usage. Idarucizumab, a recently introduced drug, is used in reversing the dabigatran effect in cases of lethal bleeding or acute surgery and invasive procedures. However, little data are available on the efficacy and safety of idarucizumab in geriatric patients. Here, we present a case of the successful administration of idarucizumab in a geriatric patient with incarcerated bowel hernia.

Keywords: Antidota, Antikoagulancia, Fibrilace síní

Revised: September 1, 2018; Accepted: September 21, 2018; Published: December 15, 2019  Show citation